Literature DB >> 19619989

Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).

Dilip Mathai, Douglas J Biedenbach, Ronald N Jones, Jan M Bell, John Turnidge, Helio S Sader.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619989     DOI: 10.1016/j.ijantimicag.2009.06.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  5 in total

1.  Daptomycin resistance in methicillin-resistant Staphylococcus aureus: a report from Southern India.

Authors:  Anantabotla Vamsimohan; Soham Gupta; Sethumadhavan Muralidharan
Journal:  Germs       Date:  2014-09-01

2.  Clinical, epidemiological, and microbiological profile of patients with vancomycin-resistant enterococci from a tertiary care hospital.

Authors:  Pr Vidyalakshmi; R Gopalakrishnan; V Ramasubramanian; K Abdul Ghafur; P Senthur Nambi; Ma Thirunarayana
Journal:  J Glob Infect Dis       Date:  2012-04

3.  Glycopeptide resistance in gram-positive cocci: a review.

Authors:  S Sujatha; Ira Praharaj
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-06-19

Review 4.  The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Zahra Chegini; Alex van Belkum; Mehdi Mirzaii; Seyed Sajjad Khoramrooz; Davood Darban-Sarokhalil
Journal:  Antimicrob Resist Infect Control       Date:  2020-04-22       Impact factor: 4.887

5.  In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.

Authors:  Sheetal Chitnis; Gunjan Katara; Nanda Hemvani; Siddika Pareek; Dhananjay Sadashiv Chitnis
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.